Silo Pharma, Inc.

NasdaqCM:SILO Stock Report

Market Cap: US$4.9m

Silo Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Eric Weisblum

Chief executive officer

US$630.1k

Total compensation

CEO salary percentage55.55%
CEO tenure12.9yrs
CEO ownership1.6%
Management average tenureno data
Board average tenure5.1yrs

Recent management updates

Recent updates

Silo Pharma's (NASDAQ:SILO) Groundbreaking Therapies Could Change The Treatment Landscape For PTSD, Fibromyalgia, MS & Alzheimer’s

May 27
Silo Pharma's (NASDAQ:SILO) Groundbreaking Therapies Could Change The Treatment Landscape For PTSD, Fibromyalgia, MS & Alzheimer’s

Narrative update from CMCVentures

SP-26 Achieves Major Preclinical Milestone, Paving the Way for First At-Home Ketamine Therapy for Fibromyalgia.Silo Pharma has just reported encouraging preclinical results for SP-26, its innovative k

Narrative update from CMCVentures

SP-26 Achieves Major Preclinical Milestone, Paving the Way for First At-Home Ketamine Therapy for FibromyalgiaSilo Pharma has just reported encouraging preclinical results for SP-26, its innovative ke

Groundbreaking therapies that could change the treatment landscape for PTSD, fibromyalgia, MS & Alzheimer’s

Silo Pharma is advancing a diversified pipeline of innovative therapies aimed at major health challenges in Central Nervous System (CNS) disorders like PTSD, fibromyalgia, Alzheimer’s, and multiple sc

Silo Pharma spikes on pre-clinical data for Alzheimer's candidate

Oct 20

Silo Pharma begins pre-IND process for topical ketamine formulation for fibromyalgia

Oct 03

CEO Compensation Analysis

How has Eric Weisblum's remuneration changed compared to Silo Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$5m

Jun 30 2025n/an/a

-US$5m

Mar 31 2025n/an/a

-US$5m

Dec 31 2024US$630kUS$350k

-US$4m

Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$3m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$569kUS$350k

-US$4m

Sep 30 2023n/an/a

-US$4m

Jun 30 2023n/an/a

-US$5m

Mar 31 2023n/an/a

-US$4m

Dec 31 2022US$332kUS$223k

-US$4m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

US$4m

Mar 31 2022n/an/a

US$4m

Dec 31 2021US$345kUS$175k

US$3m

Sep 30 2021n/an/a

US$3m

Jun 30 2021n/an/a

-US$4m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$725kUS$115k

-US$3m

Sep 30 2020n/an/a

-US$3m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$1m

Dec 31 2019US$199kUS$91k

-US$1m

Sep 30 2019n/an/a

-US$1m

Jun 30 2019n/an/a

-US$1m

Mar 31 2019n/an/a

-US$1m

Dec 31 2018US$60kn/a

-US$969k

Compensation vs Market: Eric's total compensation ($USD630.05K) is about average for companies of similar size in the US market ($USD577.34K).

Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.

CEO

Eric Weisblum (55 yo)

12.9yrs
Tenure
US$630,051
Compensation

Mr. Eric Weisblum has been the Chief Executive Officer and Chairman of the Board of Silo Pharma, Inc. (formerly known as, Uppercut Brands Inc.) since November 27, 2015 and has been its President and Direct...

Board Members

NamePositionTenureCompensationOwnership
Eric Weisblum
Chairman12.9yrsUS$630.05k1.63%
$ 79.1k
Wayne Linsley
Independent Director5.9yrsUS$45.00k0%
$ 0
Kevin Munoz
Independent Director5.2yrsUS$25.00k0%
$ 0
Joshua Woolley
Member of Scientific Advisory Board5.1yrsno datano data
Jeff Pavell
Independent Director3.3yrsUS$25.00kno data
Corwin Yu
Member of Crypto Advisory Boardless than a yearno datano data
5.1yrs
Average Tenure
56.5yo
Average Age

Experienced Board: SILO's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/28 17:14
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Silo Pharma, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
I-Eh JenLaidlaw & Company (UK) Ltd